Signaling Scaffolds for Specificity in Neuromodulator Action

神经调节剂作用特异性的信号支架

基本信息

项目摘要

Abstract b2-adrenoceptor signaling is critical for adrenergic regulation of synaptic plasticity and neurodegeneration, and has been proposed to have therapeutic potentials for Alzheimer’s and Parkinson’s diseases. However, b- adrenoceptors (b-ARs) exhibit highly complicated pharmaceutical effects. This is exemplified by clinical results, in which b-AR drugs modulate receptor paralogs in different organs to elicit both therapeutic and clinically harmful effects at the same time. We aim to understand the signaling specificity of b2-adrenoceptors (b2-ARs), mechanisms through which they are selectively coupled to different intracellular signaling proteins and molecular effectors under different conditions. Our published and preliminary results manifest the signaling scaffold, synapse-associated protein of 97 kDa (SAP97) as an orchestrator of b2-AR signaling in hippocampal neurons. Specifically, the b-isoform of SAP97 (S97b) tethers b2-ARs and the effector voltage-gated potassium channel subunit Kv1.1 together to transduce activation of b2-AR signaling into inhibition of Kv1.1 and its removal from the dendrite surface (collectively referred to as Kv1.1 inhibition). Consequently, b2-AR-induced Kv1.1 inhibition increases dendritic excitability and lowers the induction threshold for long-term synaptic potentiation. Given b2-AR-signaling also regulates the phosphorylation of the AMPA receptor subunit GluA1, but through a different signaling scaffold, we hypothesize that signaling scaffolds mediate the signaling specificity and the interactions can be used as specific pharmacological targets. In this proposal, using the S97b/b2-AR/Kv1.1 complex as an exemplary model, we aim to gain mechanistic insights into a) how the diverse b2-AR signaling events are specifically regulated; b), what the molecular components of the S97b/b2-AR/Kv1.1 complex are to achieve signaling specificity; and c) what are the behavioral correlates of the S97b/b2-AR/Kv1.1 signaling pathway in mice. Importantly, in SAP97-lacking neurons, the signaling pathway governing b2-AR dependent dendritic excitability is impaired with a ~100% penetrance, allowing an analysis with minimal confounding effects of functional redundancy. The outcomes of our proposed experiments will provide a set of mechanistically clear drug targets for treating psychiatric, neurological, immunological or cardiovascular disorders, and perhaps more importantly lead to a novel and generalizable molecular scheme, through which G-protein-coupled receptors achieve biased and selective regulations of specific effector proteins to modulate synaptic transmission and plasticity.
抽象的 B2-肾上腺素受体信号传导对于突触可塑性和神经变性的肾上腺素能调节至关重要 已提议为阿尔茨海默氏症和帕金森氏病具有治疗潜力。但是,b- 肾上腺受体(B-AR)暴露了高度复杂的药物效应。临床结果证明了这一点 其中B-AR药物调节不同器官中的受体旁系同源物,以引起治疗和临床 同时有害影响。我们旨在了解B2-肾上腺素受体(B2-AR)的信号传导特异性, 它们选择性耦合到不同细胞内信号蛋白的机制和 分子效应在不同条件下。我们发布的初步结果表明了信号 97 kDa(SAP97)的脚手架,突触相关蛋白作为海马中B2-AR信号的编排 神经元。具体而言,SAP97(S97B)Tethers B2-AR的B-异型和效应器电压门控钾 通道亚基KV1.1一起将B2-AR信号的激活转化为KV1.1的抑制作用及其去除 从树突表面(共同称为KV1.1抑制)。因此,B2AR诱导的KV1.1 抑制作用增加了树突状兴奋,并降低了长期突触潜力的诱导阈值。 给定B2-AR信号还可以调节AMPA受体亚基GLUA1的磷酸化,但通过A 不同的信号支架,我们假设信号脚手架介导信号传导特异性和 相互作用可以用作特定的药物靶标。在此提案中,使用S97B/B2-AR/KV1.1 复杂作为模范模型,我们旨在获取机械洞察力a)潜水员B2-ar信号如何传导 事件受到特别调节; b)S97b/b2-ar/kv1.1复合物的分子成分是什么 成就信号传导特异性; c)S97b/b2-ar/kv1.1信号通路的行为相关性是什么 在老鼠中。重要的是,在SAP97占用神经元中,控制B2-AR依赖性树突状的信号通路 兴奋性受到约100%的渗透率的损害,从而使分析具有最小的混杂作用 功能冗余。我们提出的实验的结果将提供一组机械清晰的 治疗精神病,神经学,免疫或心血管疾病的药物靶标,也许更多 重要的是导致一种新颖且可推广的分子方案,通过该方案G蛋白偶联受体 实现特定效应蛋白的有偏见和选择性法规,以调节突触传播和 可塑性。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据

数据更新时间:2024-06-01

Oliver Schlueter的其他基金

Signaling Scaffolds for Specificity in Neuromodulator Action
神经调节剂作用特异性的信号支架
  • 批准号:
    10350625
    10350625
  • 财政年份:
    2019
  • 资助金额:
    $ 36.22万
    $ 36.22万
  • 项目类别:

相似国自然基金

ABHD6与AMPA受体结合位点的鉴定及该位点在AMPA受体转运和功能调控中的作用研究
  • 批准号:
    32300794
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
SNX32棕榈酰化修饰调控AMPA受体介导的突触可塑性在AD中的作用机制
  • 批准号:
    32360219
  • 批准年份:
    2023
  • 资助金额:
    35 万元
  • 项目类别:
    地区科学基金项目
翻译水平选择性调控皮层AMPA受体表达促进神经元形态功能发育及神经环路塑造的分子机制及生理功能研究
  • 批准号:
    32360194
  • 批准年份:
    2023
  • 资助金额:
    31 万元
  • 项目类别:
    地区科学基金项目
AMPA受体正向变构调节剂快速抗抑郁作用及其神经机制研究
  • 批准号:
    82371524
  • 批准年份:
    2023
  • 资助金额:
    47 万元
  • 项目类别:
    面上项目
基于奖赏环路内AMPA受体相关的突触可塑性变化探讨痫蛋白在抑郁症发病中的作用及机制
  • 批准号:
    82360277
  • 批准年份:
    2023
  • 资助金额:
    32.2 万元
  • 项目类别:
    地区科学基金项目

相似海外基金

Signaling Scaffolds for Specificity in Neuromodulator Action
神经调节剂作用特异性的信号支架
  • 批准号:
    10350625
    10350625
  • 财政年份:
    2019
  • 资助金额:
    $ 36.22万
    $ 36.22万
  • 项目类别:
PKA targeting: A novel mechanism for GPCR resensitization
PKA 靶向:GPCR 再敏化的新机制
  • 批准号:
    7580680
    7580680
  • 财政年份:
    2008
  • 资助金额:
    $ 36.22万
    $ 36.22万
  • 项目类别:
PKA targeting: A novel mechanism for GPCR resensitization
PKA 靶向:GPCR 再敏化的新机制
  • 批准号:
    8212500
    8212500
  • 财政年份:
    2008
  • 资助金额:
    $ 36.22万
    $ 36.22万
  • 项目类别:
PKA targeting: A novel mechanism for GPCR resensitization
PKA 靶向:GPCR 再敏化的新机制
  • 批准号:
    7751934
    7751934
  • 财政年份:
    2008
  • 资助金额:
    $ 36.22万
    $ 36.22万
  • 项目类别:
Regulation of AKAP79 Postsynaptic Membrane Targeting
AKAP79 突触后膜靶向的调节
  • 批准号:
    7472488
    7472488
  • 财政年份:
    2001
  • 资助金额:
    $ 36.22万
    $ 36.22万
  • 项目类别: